期刊
OBESITY
卷 22, 期 5, 页码 1238-1245出版社
WILEY
DOI: 10.1002/oby.20625
关键词
-
资金
- National Institutes of Health [DK68596]
- RNB [DK29867, DK27619]
- Janssen Pharmaceutica
- Sanofi-Aventis
- Amylin Pharmaceuticals
- American Diabetes Association mentor-based fellowship
Objective: Insulin resistance is a powerful risk factor for Type 2 diabetes and a constellation of chronic diseases, and is most commonly associated with obesity. We examined if factors other than obesity are more substantial predictors of insulin sensitivity under baseline, nonstimulated conditions. Methods: Metabolic assessment was performed in healthy dogs (n = 90). Whole-body sensitivity from euglycemic clamps ( SICLAMP) was the primary outcome variable, and was measured independently by IVGTT (n = 36). Adiposity was measured by MRI (n = 90), and glucose-stimulated insulin response was measured from hyperglycemic clamp or IVGTT (n = 86 and 36, respectively). Results: SICLAMP was highly variable (5.9-75.9 dl/min per kg per mu U/ml). Despite narrow range of body weight (mean, 28.7 +/- 0.3 kg), adiposity varied approximately eight-fold and was inversely correlated with SICLAMP (P< 0.025). SICLAMP was negatively associated with fasting insulin, but most strongly associated with insulin clearance. Clearance was the dominant factor associated with sensitivity (r = 0.53, P< 0.00001), whether calculated from clamp or IVGTT. Conclusions: These data suggest that insulin clearance contributes substantially to insulin sensitivity, and may be pivotal in understanding the pathogenesis of insulin resistance. We propose the hyperinsulinemia due to reduction in insulin clearance is responsible for insulin resistance secondary to changes in body weight.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据